Form 8-K Zynerba Pharmaceuticals, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold
July 1, 2020 7:18 AM EDT(Updated - July 1, 2020 7:22 AM EDT)
(updating comment)
Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.
The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More
